LRRK2 Degraders for Parkinson's Disease and Inflammation: Tau and α‑Synuclein Degraders for Neurodegeneration.

Two complementary PROTAC classesbenzimidazole-anchored degraders of LRRK2 and pyrrolopyridine-based scaffolds for tau and α-synuclein clearancedemonstrate subnanomolar degradation potency, improved SAR over phthalimide comparators, and translational positioning for Parkinson's disease and tauopathies. Together, they highlight the therapeutic convergence of chemically differentiated anchors and robust degradation assays in advancing CNS-targeted protein degradation modalities.